- Home
- CNX vs CORT Comparison
CNX vs CORT Comparison
Compare CNX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | CORT |
|---|---|---|
| Founded | 1860 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 8.6B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNX | CORT |
|---|---|---|
| Price | $37.04 | $73.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $34.50 | ★ $130.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | 0.87 |
| Revenue | ★ $1,930,542,000.00 | $741,172,000.00 |
| Revenue This Year | $49.64 | $23.96 |
| Revenue Next Year | $2.18 | $43.40 |
| P/E Ratio | ★ $18.26 | $91.38 |
| Revenue Growth | ★ 40.99 | 17.92 |
| 52 Week Low | $27.00 | $49.00 |
| 52 Week High | $42.13 | $117.33 |
Technical Indicators
Market Signals| Indicator | CNX | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 34.53 |
| Support Level | $36.36 | $80.38 |
| Resistance Level | $37.99 | $85.34 |
| Average True Range (ATR) | 1.11 | 3.62 |
| MACD | -0.39 | -1.21 |
| Stochastic Oscillator | 13.58 | 1.22 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.